• The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
  • Subscribe
  • Sign in
  • Pharma
  • Medtech
  • Biotech
  • Science
  • Events
  • Careers
  • Jobs
  • Opinion & Debate
  • The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
Menu
  • Subscribe
  • Sign in

No 01 2023

QTE Development

-

February 1, 2023

Share article on X
Share article on Linkedin

Updated: January 31, 2025, 09:21 am

Published: February 1, 2023

Top stories

Collaboration – November 10, 2026

Mendus and NorthX to make memory NK cells

Mendus has been granted SEK 977,300 by Vinnova to establish manufacturing of memory NK cell therapies with its partner NorthX Biologics, alongside the ongoing large-scale production of its lead candidate vididencel.

Intellectual Property – November 10, 2026

US patent extends fostrox protection to 2044

The US Patent and Trademark Office has granted Medivir a patent covering fostrox in combination with lenvatinib for liver cancer, with protection now running until at least January 2044, almost three years longer than previously communicated.

Clinical Trials – November 10, 2026

Survodutide passes Phase 3 heart safety test

Boehringer Ingelheim’s obesity drug survodutide, licensed from Zealand Pharma, did not increase the risk of major cardiovascular events compared with placebo in the Phase 3 SYNCHRONIZE-CVOT trial. With this result, the registrational SYNCHRONIZE program in obesity is complete.

Pharma Business – November 10, 2026

EU approves earlier use of Oncopeptides’ Pepaxti

The European Commission has approved an expanded label for Oncopeptides’ Pepaxti (melflufen) in multiple myeloma. The drug can now be used in adults who have received at least two prior lines of therapy and whose disease is refractory to lenalidomide and the last line of therapy.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

Related posts

Collaboration - November 10, 2026

Mendus and NorthX to make memory NK cells

Mendus has been granted SEK 977,300 by Vinnova to establish manufacturing of memory NK cell therapies with its partner NorthX Biologics, alongside the ongoing large-scale production of its lead candidate vididencel.

Intellectual Property - November 10, 2026

US patent extends fostrox protection to 2044

The US Patent and Trademark Office has granted Medivir a patent covering fostrox in combination with lenvatinib for liver cancer, with protection now running until at least January 2044, almost three years longer than previously communicated.

Clinical Trials - November 10, 2026

Survodutide passes Phase 3 heart safety test

Boehringer Ingelheim’s obesity drug survodutide, licensed from Zealand Pharma, did not increase the risk of major cardiovascular events compared with placebo in the Phase 3 SYNCHRONIZE-CVOT trial. With this result, the registrational SYNCHRONIZE program in obesity is complete.

Pharma Business - November 10, 2026

EU approves earlier use of Oncopeptides’ Pepaxti

The European Commission has approved an expanded label for Oncopeptides’ Pepaxti (melflufen) in multiple myeloma. The drug can now be used in adults who have received at least two prior lines of therapy and whose disease is refractory to lenalidomide and the last line of therapy.

In a new job - November 10, 2026

Getinge appoints Stacy Beske to lead Acute Care Therapies

Getinge has appointed Stacy Beske as President of Acute Care Therapies and a member of the executive management team. She will report to President and CEO Mattias Perjos and take up the role on December 1, 2026.

In a new job - November 9, 2026

Malin Parkler takes on European role at Pfizer

Malin Parkler, who has led Pfizer’s Swedish organization for more than a decade, will take on a one-year assignment as Europe Cluster Lead, Global Hospital & Biosimilars, on December 1, 2026. Caglar Ceritoglu, North Europe Cluster President, will step in as Acting Country Lead in Sweden.

Pharma article - November 9, 2026

Opioid treatment linked to lower societal costs

Each person with opioid dependence who starts or stays in treatment for a year is associated with an estimated GBP 140,876 in lower societal costs in the UK. That is the finding of a new study by Lund-based Camurus and the Swedish Institute for Health Economics (IHE).

Sign up to our newsletter: Nordic Life Science News!

I confirm that I want to subscribe to newsletters from Nordic Life Science and that Nordic Life Science has the right to save my email address. Read our privacy policy here

Read the latest issue!

Sign up for a subscription and read our latest digital issue today.

Sign up
Sign up

The leading life science news channel in the Nordic region.

© NLS Media Group AB – All rights reserved

Digital and print
  • The magazine
  • Subscribe
  • Newsletter
More information
  • About us
  • Contact
  • Advertising
Social media
  • LinkedIn
  • Bluesky
  • X
NLS Media Group AB

St Paulsgatan 13

118 46 Sweden

info@nlsnews.com

+46-8-588 941 51

  • Cookies
  • Data management and privacy policy

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.